Reduction of Heparin Dose in Dialysis With Evodial System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2010-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current clinical study aims at defining an index of Anti Xa, which is the marker to evaluate the activity of heparin, at the end of the dialysis treatment and so showing the possibility to decrease heparin doses during hemodialysis when using Evodial hemodialyzer. Actually, an elevated value of AntiXa at the end of the dialysis treatment increases the risk of bleeding for patients with diabetic retinopathy, or for instance in case of fall at home.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HepZero:Heparin Free Dialysis With Evodial

NCT01318486

Chronic Kidney Disease Patients Requiring Heparin Free Dialysis Treatments

COMPLETED NA

Heparin Free Haemodialysis With Haemodialyzers "VIE" Versus "EVODIAL"

NCT01221337

Adult Chronic Haemodialysis Patients Since at Least 3 Months

COMPLETED NA

Chronic Hemodialysis Without Systemic Heparinization : a Randomized Study

NCT00473109

Contra-Indication to the Use of Low Molecular Weight Heparin

COMPLETED PHASE3

A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis

NCT01181544

Renal Failure Chronic Requiring Hemodialysis

COMPLETED NA

Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +)

NCT01783626

End Stage Renal Disease (ESRD)

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In parallel to the new hemodialyzer, Evodia blood lines were developed to improve characteristics of the extracorporeal circuit in term of reduced activation of the coagulation system and lower deposits of clot components.

The aim is to provide a system (hemodialyzer and extracorporeal circuit) with a low thrombogenicity and that can be used with low heparin dose in order to reduce the patients' bleeding risk at the end of HD treatment.

Measurements of TAT (Thrombin-Antithrombin), the marker of the activation of the coagulation, will be performed during the study in order to evaluate the thrombogenicity of the system.

The ionic clearance will be collected during all treatments to evaluate the performance of the hemodialyzer.

The study will be divided into three steps

* Period 1: Usual heparin dose with usual hemodialyzer and standard blood lines (baseline),
* Period 2: Decrease of heparin dose with Evodial hemodialyzer and standard bloodlines
* Period 3: Lowest heparin dose defined in step 2 using the system Evodial hemodialyzer and SMA bloodlines.

Each patient included into the study will perform the three steps. As the risk of extracorporeal circuit clotting will be rather important, no control group (usual hemodialyzer with heparin decrease dose) will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Treatment with Evodial with reduction of heparin across study period

Group Type EXPERIMENTAL

Evodial hemodialysers and Evodia blood lines

Intervention Type DEVICE

Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evodial hemodialysers and Evodia blood lines

Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients suffering from chronic renal failure,
* Patients treated in HD three times a week for at least 3 months, with a stable heparin dose and the same filter,
* Patients treated in 4-4.5 hours HD mode with a blood flow between 300-350 ml/min,
* Patients for whom either LMWH (Enoxaparin, Nadroparin, Tinzaparin) or UFH is used,
* Patients with a well-functioning vascular access as judged by the investigator,
* Patients treated either on AK, Innova or Integra dialysis machines equipped with ionic dialysance device,
* Patients older than 18 years,
* Patients with negative serologies (AIDS, Hepatitis)
* Patients having signed consent to participate in the study.

Exclusion Criteria

* Patient with HIT or known heparin allergy,
* Patient treated in HD in single needle mode,
* Patients with catheter,
* Patients with acute inflammatory event that may affect, as judged by investigator patients' safety or study results,
* Patients participating in other studies that could interfere with the objective of this study,
* Patients with active malignant disease,
* Patients receiving heparin outside dialysis treatment,
* Patients under guardianship,
* Pregnant women, nursing mothers and women planning a pregnancy during the course of this study,
* Patients with serious history of coagulopathy,
* Patients receiving Anti-Vitamin K medication,
* Patients receiving an association of anti platelets agents,
* Patients with heparin dose that can not be reduced for technical reason (excluding patients receiving too low heparin dose with no possibility of further reduction).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No